Zydus announces USFDA Orphan Drug Designation to Usnoflast for the treatment of Amyotrophic Lateral Sclerosis (ALS) Read more
Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules Read more
Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS) Read more